Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function (Q57491711)

30 June 2019

title

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function (English)

1 reference

30 June 2019

1 reference

0 references

16

1 reference

30 June 2019

Robin Goland

6

Robin Goland

1 reference

30 June 2019

Carla J Greenbaum

2

Carla J Greenbaum

1 reference

30 June 2019

Darrell M. Wilson

15

Darrell M Wilson

1 reference

30 June 2019

Jay S Skyler

17

Jay S Skyler

1 reference

30 June 2019

Dorothy J Becker

4

Dorothy J Becker

1 reference

30 June 2019

author name string

Heidi Krause-Steinrauf

3

1 reference

30 June 2019

Philip Raskin

11

1 reference

30 June 2019

Henry Rodriguez

12

1 reference

30 June 2019

Diane Wherrett

14

1 reference

30 June 2019

Mark D Pescovitz

1

1 reference

30 June 2019

Stephen E Gitelman

5

1 reference

30 June 2019

Peter A Gottlieb

7

1 reference

30 June 2019

Jennifer B Marks

8

1 reference

30 June 2019

Paula F McGee

9

1 reference

30 June 2019

Antoinette M Moran

10

1 reference

30 June 2019

Desmond A Schatz

13

1 reference

30 June 2019

Type 1 Diabetes TrialNet Anti-CD20 Study Group

18

1 reference

30 June 2019

language of work or name

English

0 references

publication date

1 November 2009

1 reference

30 June 2019

The New England Journal of Medicine

published in

1 reference

30 June 2019

volume

361

1 reference

30 June 2019

issue

22

1 reference

30 June 2019

page(s)

2143-2152

1 reference

30 June 2019

Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis.

cites work

1 reference

12 December 2020

I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice

1 reference

12 December 2020

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

1 reference

12 December 2020

1 reference

12 December 2020

Development of type 1 diabetes despite severe hereditary B-cell deficiency

1 reference

12 December 2020

T cell activation in rheumatoid synovium is B cell dependent

1 reference

12 December 2020

Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations.

1 reference

12 December 2020

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

1 reference

12 December 2020

The role of B lymphocytes as key antigen-presenting cells in the development of T cell-mediated autoimmune type 1 diabetes

1 reference

12 December 2020

CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.

1 reference

12 December 2020

The role of t/b lymphocyte collaboration in the regulation of autoimmune and alloimmune responses

1 reference

12 December 2020

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

1 reference

12 December 2020

C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.

1 reference

12 December 2020

The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation

1 reference

12 December 2020

Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses

1 reference

12 December 2020

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

12 December 2020

Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174.

1 reference

12 December 2020

Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases

1 reference

12 December 2020

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

1 reference

12 December 2020

Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action

1 reference

12 December 2020

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

12 December 2020

Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments

1 reference

12 December 2020

Rituximab treatment of idiopathic membranous nephropathy

1 reference

12 December 2020

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes

1 reference

12 December 2020

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

1 reference

12 December 2020

GAD treatment and insulin secretion in recent-onset type 1 diabetes

1 reference

12 December 2020

Immunologic responses to bacteriophage ϕX 174 in immunodeficiency diseases

1 reference

12 December 2020

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

12 December 2020

Lessons learned from use of cyclosporine for insulin-dependent diabetes mellitus. The case for immunotherapy for insulin-dependent diabetics having residual insulin secretion

1 reference

12 December 2020

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

Immunoprotection in spontaneous remission of type 1 diabetes: long-term follow-up results

1 reference

12 December 2020

Progress in the immunointervention of type-1 diabetes mellitus

1 reference

12 December 2020

B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice

1 reference

12 December 2020

Identifiers

DOI

10.1056/NEJMOA0904452

1 reference

30 June 2019

PMCID

6410357

1 reference

30 June 2019

PubMed ID

19940299

1 reference

30 June 2019